{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:29:01Z","timestamp":1790011741458,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008092","name":"Jinhua City Science and Technology Bureau","doi-asserted-by":"publisher","award":["2023-3-060"],"award-info":[{"award-number":["2023-3-060"]}],"id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bmcl.2026.130668","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:29:22Z","timestamp":1777930162000},"page":"130668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel probe-quality EGFR degraders targeting wild-type and Del19 mutation"],"prefix":"10.1016","volume":"138","author":[{"given":"Xiaomeng","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130668_bb0005","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000279388","article-title":"EGFR signaling and drug discovery","volume":"77","author":"Lurje","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.bmcl.2026.130668_bb0010","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2026.130668_bb0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/apm.12328","article-title":"The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population","volume":"123","author":"Skov","year":"2015","journal-title":"Apmis"},{"key":"10.1016\/j.bmcl.2026.130668_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130668_bb0025","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmcl.2026.130668_bb0030","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s43018-022-00351-8","article-title":"An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer","volume":"3","author":"To","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bmcl.2026.130668_bb0035","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2026.130668_bb0045","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bmcl.2026.130668_bb0050","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1021\/jacs.5c14840","article-title":"Allosteric PROTACs: expanding the horizon of targeted protein degradation","volume":"148","author":"Frost","year":"2026","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2026.130668_bb0055","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.drudis.2021.02.005","article-title":"Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma","volume":"26","author":"Tripathi","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmcl.2026.130668_bb0060","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1021\/acs.jmedchem.1c01827","article-title":"Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands","volume":"65","author":"Zhao","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/acsmedchemlett.1c00657","article-title":"Bifunctional compounds as SMARCA2 degraders for treating cancer","volume":"13","author":"Sabnis","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130668_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/C0MB00074D","article-title":"Impact of linker length on the activity of PROTACs","volume":"7","author":"Cyrus","year":"2011","journal-title":"Mol BioSyst"},{"key":"10.1016\/j.bmcl.2026.130668_bb0075","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0080","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.1103966","article-title":"Autophagy defends cells against invading group A Streptococcus","volume":"306","author":"Nakagawa","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2026.130668_bb0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/164_2016_5000","article-title":"8-nitro-cGMP: a novel protein-reactive cNMP and its emerging roles in autophagy","volume":"238","author":"Arimoto","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130668_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107466","article-title":"Autophagy mediated targeting degradation, a promising strategy in drug development","volume":"149","author":"Zhang","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2021.122184","article-title":"Real-time tracking lysosomal pH changes under heatstroke and redox stress with a novel near-infrared emissive probe","volume":"228","author":"Xia","year":"2021","journal-title":"Talanta"},{"key":"10.1016\/j.bmcl.2026.130668_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117212","article-title":"Recent advances in developing targeted protein degraders","volume":"284","author":"Cheng","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0105","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1021\/acs.jpcb.4c07651","article-title":"Identification of novel fourth-generation allosteric inhibitors targeting inactive state of EGFR T790M\/L858R\/C797S and T790M\/L858R mutations: a combined machine learning and molecular dynamics approach","volume":"129","author":"Bhanja","year":"2025","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.bmcl.2026.130668_bb0110","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/ja017277z","article-title":"Total synthesis of ustiloxin D","volume":"124","author":"Cao","year":"2002","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2026.130668_bb0115","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1021\/acsomega.8b00159","article-title":"A simple and versatile method for the formation of acetals\/ketals using trace conventional acids","volume":"3","author":"Dong","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2026.130668_bb0120","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","article-title":"Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer","volume":"64","author":"Han","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0125","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically induced degradation of Sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals)","volume":"61","author":"Schiedel","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113150","article-title":"Discovery of a PROTAC targeting ALK with in vivo activity","volume":"212","author":"Yan","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0135","doi-asserted-by":"crossref","first-page":"12342","DOI":"10.1021\/acs.jmedchem.3c00861","article-title":"Second-generation AUTACs for targeted autophagic degradation","volume":"66","author":"Takahashi","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0140","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2026.130668_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108991","article-title":"Quinazoline-based fourth-generation EGFR tyrosine kinase inhibitors to overcome C797S-mediated resistance in non-small cell lung cancer (NSCLC)","volume":"165","author":"Patil","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130668_bb0150","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.bmcl.2026.130668_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70338","article-title":"Responsiveness of different MET tumour alterations to type I and type II MET inhibitors","volume":"15","author":"Murciano-Goroff","year":"2025","journal-title":"Clin Transl Med"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:19:48Z","timestamp":1783160388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S0960894X26001356"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130668","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel probe-quality EGFR degraders targeting wild-type and Del19 mutation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130668"}}